In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer buying Coley for $164mm

Executive Summary

Following two years of collaboration, Pfizer is stepping up its relationship with Coley Pharmaceuticals by purchasing the public vaccine adjuvant and immunotherapeutics developer for $8 per share, or a total of about $213mm ($165mm after subtracting Coley's net cash balance). The per share price represents a 154% premium over Coley's preannouncement market average.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies